Cynthia Garcia, APRN
Psychiatric/Mental Health · San Antonio, TXNPI 1689249666
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- AbbVie$787
- Neurocrine Biosciences, Inc.$766
- Otsuka America Pharmaceutical, Inc.$735
- plus $2K from 10 others
What the payments were for
- Food & beverage$8,75397%
- Education$2403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 91 | $1,945 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,240 |
| Alkermes, Inc. | 40 | $1,077 |
| AbbVie | 47 | $787 |
| Neurocrine Biosciences, Inc. | 51 | $766 |
| Otsuka America Pharmaceutical, Inc. | 39 | $735 |
| Axsome Therapeutics, Inc. | 21 | $509 |
| E.r. Squibb & Sons, L.L.C. | 21 | $504 |
| Lundbeck LLC | 22 | $457 |
| Johnson & Johnson | 18 | $389 |
| Vanda Pharmaceuticals Inc. | 18 | $386 |
| Sunovion Pharmaceuticals Inc. | 5 | $61 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Medline Industries LP | 1 | $32 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$250
- CAPLYTA$250
- Austedo XR$250
- UZEDY$242
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Fanapt$122
- Auvelity$104
How this compares
$8,994 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 22 | $184,046 |
| IngrezzaValbenazine Tosylate | 15 | $126,287 |
| Lurasidone Hcl | 61 | $43,152 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,742 |
| RexultiBrexpiprazole | 19 | $29,130 |
| Abilify MaintenaAripiprazole | 13 | $28,328 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,866 |
| VraylarCariprazine Hcl | 17 | $24,746 |
| Varenicline Tartrate | 30 | $8,931 |
| Aripiprazole | 190 | $8,887 |
| Clozapine | 37 | $6,568 |
| Duloxetine Hcl | 166 | $5,371 |
| Hydroxyzine Hcl | 88 | $4,520 |
| Ziprasidone Hcl | 44 | $4,470 |
| Divalproex Sodium ErDivalproex Sodium | 59 | $3,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $389 | $222,78733 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $766 | $126,28715 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $735 | $57,45832 claims |
| Alkermes, Inc.Lybalvi | $1,077 | $24,86615 claims |
| AbbVieVraylar | $787 | $24,74617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in San Antonio
- Monique GonzalezSan Antonio$126K
- Geoffrey GonzalesSan Antonio$57K
- Sara Koenig LangstonSan Antonio$27K
- Peter TorciviaSan Antonio$13K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.